STOCK TITAN

Takeda (NYSE: TAK) director reports RSU and share holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

TAKEDA PHARMACEUTICAL CO LTD director Miki Tsusaka has reported initial equity interests in the company. The filing shows direct ownership of 6,400 Ordinary Shares. It also lists restricted stock units that vest in tranches of 2,100 shares on June 1, 2026, 2,200 shares on June 1, 2027 and 2,100 shares on June 1, 2028. In addition, the report includes Tax Obligation Awards that are each economically equivalent to one Ordinary Share and are designed to be settled in cash at future vesting dates primarily to cover tax obligations.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Tsusaka Miki

(Last)(First)(Middle)
SHINAGAWA GRAND CENTRAL TOWER
16-3, KONAN 2-CHOME, MINATO-KU

(Street)
TOKYO108-0075

(City)(State)(Zip)

JAPAN

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026
3. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares6,400(1)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Tax Obligation Award06/01/202606/01/2026Ordinary Shares2,152(2)D
Tax Obligation Award06/01/202706/01/2027Ordinary Shares2,392(2)D
Tax Obligation Award01/01/202801/01/2028Ordinary Shares2,280(2)D
Explanation of Responses:
1. Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest on the following schedule: June 1, 2026 (2,100 shares), June 1, 2027 (2,200 shares) and June 1, 2028 (2,100 shares).
2. Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
Remarks:
Exhibit 24 Power of Attorney
/s/ Max Heuer, by power of attorney, for Miki Tsusaka03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Takeda (TAK) director Miki Tsusaka report owning on this Form 3?

Director Miki Tsusaka reports direct ownership of 6,400 Ordinary Shares of Takeda. The filing also lists restricted stock units and Tax Obligation Awards tied to additional Ordinary Shares that will vest or settle in the future under specified schedules.

How many Takeda (TAK) restricted stock units are scheduled to vest for Miki Tsusaka?

The Form 3 describes RSUs that vest in three tranches: 2,100 shares on June 1, 2026, 2,200 shares on June 1, 2027, and 2,100 shares on June 1, 2028. Each RSU represents a contingent right to receive one Ordinary Share.

What are the Tax Obligation Awards disclosed for Takeda (TAK) director Miki Tsusaka?

Tax Obligation Awards are instruments economically equivalent to one Ordinary Share that convert into cash upon vesting. The cash is intended primarily to cover tax obligations based on the then-current market price of Takeda Ordinary Shares, rather than delivering additional shares.

What future dates matter for the Tax Obligation Awards held by Takeda (TAK) director Miki Tsusaka?

The filing shows Tax Obligation Awards linked to Ordinary Shares with key dates of June 1, 2026, June 1, 2027, and January 1, 2028. These dates correspond to when the awards are scheduled to vest and ultimately expire if not previously settled.

Does this Takeda (TAK) Form 3 show any share purchases or sales by Miki Tsusaka?

No open-market purchases or sales are indicated. The entries are categorized as holdings, detailing existing Ordinary Shares, restricted stock units, and Tax Obligation Awards, rather than new buy or sell transactions in Takeda’s stock on the reported date.
Takeda Pharm

NYSE:TAK

View TAK Stock Overview

TAK Rankings

TAK Latest News

TAK Latest SEC Filings

TAK Stock Data

57.06B
3.16B
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Japan
Tokyo